Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, summarizes the results of the Phase IIb trial (NCT02953652) assessing HBI-8000, a histone deacetylase inhibitor (HDACI), in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 55 patients were enrolled with a durable response rate reported. Patients with angioimmunoblastic T-cell lymphoma (AITL) additionally had a higher response rate, suggesting an increased role of HDACIs and demethylating agents in treating ATIL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

свернуть